PSNL
Personalis Inc
Chart
Technical data
$11.98
1.70%
$1.22
95
$13.89 (-13.7%)
$11.43 (+4.8%)
$8.97 (+33.5%)
$8.96 (+33.7%)
$16.39 (-26.9%)
$3.84 (+212.0%)
4.20M
1.24
2026-07-27
18
Advancing
500
36.77%
38.20%
9.25%
1.19
15
94%
570
1254
2026-07-29
$8.51
22
2026-07-27
Upcoming confluences
| Date | Price | Score | Price levels | Time levels |
|---|---|---|---|---|
| 2026-07-29 | $8.51 | 4 | 23 | 6 |
| 2026-08-05 | $8.51 | 6 | 23 | 8 |
| 2026-08-05 | $12.94 | 4 | 16 | 8 |
| 2026-08-12 | $8.51 | 6 | 23 | 9 |
| 2026-08-12 | $12.94 | 4 | 16 | 9 |
| 2026-08-19 | $8.51 | 5 | 23 | 5 |
| 2026-08-31 | $8.51 | 5 | 23 | 7 |
| 2026-08-31 | $12.94 | 4 | 16 | 7 |
| 2026-10-02 | $8.51 | 5 | 23 | 5 |
Fundamental data
Personalis Inc
Healthcare
Diagnostics & Research
$1.41B
$39.26M
70.57M
—
15.74%
3.82
68.33%
96.79%
—
95
—
Fundamental analysis
No analysis yet. This will pull the latest 10-K, 10-Q, and DEF 14A from SEC EDGAR, ingest the company's XBRL financial facts, compute Beneish / Altman / Piotroski / Sloan / Penman–Nissim, run Greenwald EPV + Mauboussin reverse-DCF, and synthesise a Columbia-style moat, earnings quality, and capital allocation review. Cached for 90 days.
News (6)
| Published (UTC) | Session | Sentiment | Category | Move % | Headline |
|---|---|---|---|---|---|
| 2026-07-21 08:30 | PreMarket |
Bullish |
AcquisitionTarget |
0.75% | Tempus AI acquires cancer-monitoring firm Personalis for $1.5 billion |
| 2026-07-21 07:43 | AfterHours |
Bullish |
AcquisitionTarget |
0.75% | Tempus AI acquires Personalis in $1.5bn precision oncology-focused deal |
| 2026-07-20 16:56 | Regular |
Bullish |
AcquisitionTarget |
-13.32% | Tempus AI Buys Personalis in $1.7 Billion Precision Oncology Deal |
| 2026-07-20 11:23 | PreMarket |
Bullish |
AcquisitionTarget |
-13.32% | Tempus AI to acquire cancer-monitoring firm Personalis for $1.5B |
| 2026-07-20 11:11 | PreMarket |
Bullish |
AcquisitionTarget |
-13.32% | TEMs Deal To Acquire PSNL Opens Door For $20B Cancer Market Opportunity Retail Awaits To See Execution |
| 2026-07-20 08:35 | PreMarket |
Bullish |
AcquisitionTarget |
-13.32% | Tempus to Acquire Personalis, More Tightly Integrating Molecular Residual Disease (MRD) into Its AI-Enabled Precision Oncology Platform |
SEC Filings (0)
No SEC filings cached for CIK 1527753 yet — run a fundamental analysis to import the last 3 years.
Beneficial Ownership 5%+ (0)
No SC 13D / 13G filings parsed for this symbol in the last 2 years.
Institutional Holders (0)
CUSIP not yet known for PSNL. Three population pathways: (1) the next fundamental analysis run extracts it from any SC 13D/G cover page filed against PSNL (cover pages print the subject-company CUSIP near the top); (2) the daily Form13FIngestionJob auto-links from a 13F-HR holding whose IssuerName uniquely matches PSNL's CompanyName; (3) manual SQL update on the Tickers row. Once linked, institutional holders appear below.
Current setups (0)
No open or triggered setups for PSNL right now.
Closed setups (0)
No closed setups yet for PSNL.